Waters Corp WAT
We take great care to ensure that the data presented and summarized in this overview for WATERS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding WAT
View all-
Vanguard Group Inc Valley Forge, PA7.02MShares$2.28 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY5.65MShares$1.83 Billion0.04% of portfolio
-
Terry Smith Fundsmith LLP | London, X03.65MShares$1.19 Billion4.42% of portfolio
-
State Street Corp Boston, MA2.53MShares$820 Million0.03% of portfolio
-
Massachusetts Financial Services CO Boston, MA2.42MShares$784 Million0.22% of portfolio
-
Alliancebernstein L.P. New York, NY2.36MShares$764 Million0.25% of portfolio
-
Generation Investment Management LLP London, X01.81MShares$588 Million2.58% of portfolio
-
Geode Capital Management, LLC Boston, MA1.4MShares$454 Million0.04% of portfolio
-
Fundsmith Investment Services Ltd. Grande Riviere Noire, O41.23MShares$398 Million4.69% of portfolio
-
Invesco Ltd. Atlanta, GA1.01MShares$327 Million0.06% of portfolio
Latest Institutional Activity in WAT
Top Purchases
Top Sells
About WAT
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Insider Transactions at WAT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2024
|
Heather Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
32
+16.0%
|
-
|
Sep 30
2024
|
Wei Jiang Director |
BUY
Grant, award, or other acquisition
|
Direct |
62
+3.07%
|
-
|
Sep 30
2024
|
Pearl S Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
75
+2.86%
|
-
|
Aug 14
2024
|
Heather Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
136
+50.0%
|
-
|
Jun 28
2024
|
Wei Jiang Director |
BUY
Grant, award, or other acquisition
|
Direct |
64
+3.27%
|
-
|
Jun 28
2024
|
Pearl S Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
76
+2.99%
|
-
|
Jun 24
2024
|
Robert L Carpio Iii SVP, Waters Division |
BUY
Grant, award, or other acquisition
|
Direct |
2,247
+33.33%
|
-
|
May 28
2024
|
Richard H Fearon Director |
BUY
Open market or private purchase
|
Direct |
1,000
+37.69%
|
$332,000
$332.9 P/Share
|
May 15
2024
|
Christopher A Kuebler Director |
SELL
Open market or private sale
|
Direct |
4,000
-21.37%
|
$1,444,000
$361.64 P/Share
|
May 15
2024
|
Christopher A Kuebler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+17.61%
|
$452,000
$113.88 P/Share
|
May 13
2024
|
Amol Chaubal SVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
145
-5.95%
|
$50,605
$349.28 P/Share
|
Apr 05
2024
|
Jianqing Bennett SVP TA Instruments Division |
SELL
Payment of exercise price or tax liability
|
Direct |
202
-6.79%
|
$67,670
$335.94 P/Share
|
Mar 13
2024
|
Linda Baddour Director |
SELL
Open market or private sale
|
Direct |
500
-18.18%
|
$177,500
$355.54 P/Share
|
Mar 01
2024
|
Udit Batra President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,584
-23.95%
|
$2,278,064
$346.04 P/Share
|
Feb 07
2024
|
Udit Batra President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,903
+36.45%
|
-
|
Jan 02
2024
|
Richard H Fearon Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+33.84%
|
-
|
Jan 02
2024
|
Mark P Vergnano Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+7.91%
|
-
|
Jan 02
2024
|
Christopher A Kuebler Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+2.22%
|
-
|
Jan 02
2024
|
Flemming Ornskov Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+7.19%
|
-
|
Jan 02
2024
|
Pearl S Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+19.35%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 14.3K shares |
---|---|
Open market or private purchase | 1K shares |
Exercise of conversion of derivative security | 4K shares |
Payment of exercise price or tax liability | 6.93K shares |
---|---|
Open market or private sale | 4.5K shares |